NCT04583722 is a NA clinical trial of AX-olive oil-PP emulsion in Bioavailability, sponsored by Yoav D. Livney.

Who is sponsoring NCT04583722?

NCT04583722 is sponsored by Yoav D. Livney.

What drugs are being tested in NCT04583722?

Interventions in NCT04583722: AX-olive oil-PP emulsion.

What condition does NCT04583722 study?

NCT04583722 studies Bioavailability.

Is NCT04583722 still recruiting?

NCT04583722 is currently completed. Last updated 1 April 2021.

Last reviewed 2021-04-01 · How we verify

NCT04583722

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Astaxanthin Bioavailability, and a New Technology for Improving it, Using Natural Food Materials Only

Completed NA Last updated 1 April 2021

What this trial tests

NA trial testing AX-olive oil-PP emulsion in Bioavailability in 13 participants. Completed in 16 January 2019.

Timeline

15 July 2018

Primary endpoint
30 November 2018

16 January 2019

Quick facts

Lead sponsor	Yoav D. Livney
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	basic science
Enrollment	13
Start date	15 July 2018
Primary completion	30 November 2018
Estimated completion	16 January 2019
Sites	1 location across Israel

Drugs / interventions tested

AX-olive oil-PP emulsion

Conditions studied

Bioavailability — all drugs for Bioavailability →

Sponsor

Yoav D. Livney

Who can join

Adults 18 to 26, any sex, with Bioavailability. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to develop a potato protein (PP)-based delivery system for increasing oral bioavailability of lipophilic bioactives (nutraceuticals and drugs), using astxanthin (AX) as a model, and to evaluate the system in vivo in a crossover clinical study in human volunteers. Three different formulations were prepared, encapsulating AX oleoresin (AXO) with (1) PP only, (2) PP+lecithin (LEC), and (3) PP+olive oil (OO). In a randomized, double-blind, crossover study in human subjects, the PP-OO-AX formulation had a 4.8-fold higher median plasma AX area under the concentration-over time curve (AUC; P\<0.001) compared to the raw AXO formulation. In conclusion, a non-allergenic, vegan, PP based delivery system made of "all-natural ingredients" offers a great promise for increasing oral bioavailability of lipophilic bioactives such as AX, for the enrichment of food and for dietary supplements, or oral delivery of lipophilic drugs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Bioavailability

Currently open trials in the same condition.

NCT07063173 — Bioavailability of Ration Items Containing Tart Cherry Extract · NA · recruiting
NCT05774704 — Curcumin and Retinal Study · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04583722 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yoav D. Livney
Last refreshed: 1 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04583722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing